膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was engineered to express NF-kB signaling response element driving luciferase expressing systems.When stimulated with human IL-17A or human IL-17F protein, receptor-mediated signaling can drive NF-kB-mediated luminescence. Neutralization of biological effect of human IL-17A or human IL-17F protein by corresponding antibody results in a decrease in luminescence.
应用说明（Application）
• Screen for neutralizing antibodies blocking the stimulation of human IL-17A or human IL-17F protein.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Zeocin (20 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Application
Inhibition of human IL-17A protein-induced reporter activity by anti-human IL-17A neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-17A protein (Cat. No. ILA-H5219) with a final concentration of 0.01 μg/mL. The EC50 of anti-human IL-17A neutralizing antibody (Bimekizumab) is approximately 0.02893 μg/mL.
Protocol
Inhibition of human IL-17F protein-induced reporter activity by anti-human IL-17F neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-17F protein (Cat. No. ILF-H5244) with a final concentration of 0.5 μg/mL. The EC50 of anti-human IL-17F neutralizing antibody (Bimekizumab) is approximately 0.6346 μg/mL.
Protocol
Signaling Bioassay
Response to human IL-17A protein (RLU).
The Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-17A protein (Cat. No. ILA-H5219). The EC50 was approximately 0.008 μg/mL.
Protocol
Response to human IL-17A protein (FOLD).
Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-17A protein (Cat. No. ILA-H5219). The max induction fold was approximately 340.
Protocol
Response to human IL-17F protein (RLU).
The Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-17F protein (Cat. No. ILF-H5244). The max induction fold was approximately 52.82.
Protocol
Response to human IL-17F protein (FOLD).
The Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-17F protein (Cat. No. ILF-H5244). The max induction fold was approximately 52.82.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-17A protein. Human IL-17A protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 12-22.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
